On August 7, PHARMARON rose 5.14% in regular trading, trading at HK$25.9/share, with turnover of HK$40.02 million. The stock gained momentum as the CXO sector continued to strengthen and the company's board meeting to review first-half results approaches on August 20.

The rally was primarily driven by sector-wide tailwinds following WuXi AppTec's strong interim results, which reported revenue growth of 38.93% year-over-year and net profit growth of 29.43%. Peers including WuXi AppTec rose 3.84% and WuXi Biologics gained 1.98% on the same session. PHARMARON previously guided H1 revenue of RMB 7.47-7.67 billion, representing 16%-19% growth, with newly signed orders surging over 30% and small-molecule CDMO orders growing over 50%.

Industry research indicates that global innovative drug primary market financing reached US$26.75 billion in H1, up 58.5% year-over-year, supporting sustained CXO sector momentum as the industry enters an earnings delivery phase.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)